Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 296 publications
Clinico-demographic Profile and Diagnostic Modalities in Patients with Pancreatobiliary Malignancy Undergoing Endoscopic Retrograde Cholangiopancreatography in a Tertiary Care Center of Nepal.
Journal: Kathmandu University medical journal (KUMJ)
Published: June 19, 2026
A guide to CAR T cell therapies: development, current status and future prospects.
Journal: Nature reviews. Immunology
Published: June 01, 2026
Pan-cancer spatial atlas of tertiary lymphoid structures.
Journal: Science (New York, N.Y.)
Published: May 28, 2026
Programming the immunological properties of mRNA vaccines for cancer.
Journal: Nature reviews. Immunology
Published: May 18, 2026
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.
Journal: ESMO open
Published: April 11, 2026
Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.
Journal: Physical review letters
Published: March 24, 2026
Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.
Journal: Physical review letters
Published: March 24, 2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 06, 2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
Journal: ESMO open
Published: February 02, 2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2026
ASO Special Article: Proceedings of the Inaugural Joint US-India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and Care.
Journal: Annals of surgical oncology
Published: January 23, 2026
Last Updated: 09/26/2026